Sales of the company's obesity drug Qsymia were the primary focus of the report, but what else should investors be paying attention to when they analyze VIVUS' quarter? In this video, health care analyst Max Macaluso discusses three essential topics that investors need to consider.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 02/20/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return